

LISTING OF CLAIMS


This listing of claims will replace all prior versions, and listings, of claims in the application.

Claims 1-17. (Cancelled)

18. (Currently amended) The compound of claim ~~47~~ 89, wherein Y^1 is hydrogen, Y^2 comprises $OC(O)R^3$, wherein R^3 is a branched or straight chain C_1 to C_{25} alkyl group, and each R^1 is an ethyl group or a sodium ion.
19. (Original) The compound of claim 18, wherein X^1 is hydrogen and X^2 is OH or $OC(O)R^3$, wherein R^3 is a branched or straight chain C_1 to C_{25} alkyl group.
20. (Currently amended) The compound of claim ~~47~~ 89, wherein X^1 is hydrogen, X^2 is $OC(O)R^3$, wherein R^3 is a branched or straight chain C_1 to C_{25} alkyl group, and each R^1 is an ethyl group or a sodium ion.
21. (Original) The compound of claim 20, wherein Y^1 is hydrogen and Y^2 is OH or $OC(O)R^3$, wherein R^3 is a branched or straight chain C_1 to C_{25} alkyl group.

22-88 (Cancelled)

89. (Previously Presented) A compound having the formula I



wherein

X^1 , X^2 , Y^1 , and Y^2 are, independently, hydrogen, fluorine, a hydroxyl group, OR^2 , $OC(O)R^3$, or $NC(O)R^3$;

Z is CF_2 ;

each R^1 is, independently, hydrogen, a branched or straight chain C_1 to C_{25} alkyl group, or a cationic counterion;

R² is hydrogen, a branched or straight chain C₁ to C₂₅ alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group or a protecting group;

R³ is a branched or straight chain C₁ to C₂₅ alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group,

wherein when Y¹ and Y² are different groups, the stereochemistry at carbon a is either R or S.

90. (Withdrawn) A method for improving wound healing in a subject in need of such improvement, comprising contacting the wound of a mammal with a compound of claim 89.
91. (Withdrawn) A method for treating or preventing in a subject a disease comprising administering to the subject a compound of claim 89.
92. (Withdrawn) The method of claim 91, wherein the disease comprises cancer or diabetes.
93. (Withdrawn) A method for reducing inflammation or an allergic response in a subject comprising administering to the subject a compound of claim 89.
94. (Withdrawn) A method for increasing or altering cardiovascular function in a subject comprising administering to the subject a compound of claim 89.
95. (Withdrawn) A method for maintaining or terminating embryonic development in a subject comprising administering to the subject a compound of claim 89.
96. (Withdrawn) A method for eliciting or inhibiting platelet aggregation in a subject comprising administering to the subject a compound of claim 89.
97. (Withdrawn) A method for increasing or inhibiting cell growth and proliferation in a culture comprising contacting the cells in the culture with a compound of claim 89.
98. (Withdrawn) A method of treating or preventing a disease in a subject comprising administering a compound of claim 89 thereof as a PPAR γ agonist.
99. (Withdrawn) A method of treating or preventing a disease in a subject comprising administering a compound of claim 89 to inhibit a lipid phosphatase, lipid kinase, or phospholipase enzyme.
100. (Withdrawn) The use of a compound of claim 89 for targeting the discovery of a drug.

ATTORNEY DOCKET NO. 24U03.1-071
PATENT

- 101. (Withdrawn) A method for growing or proliferating cells in a culture comprising administering to the cells in the culture a compound of claim 89.
- 102. (Withdrawn) A method for determining the activity of lysophosphatidic acid or phosphatidic acid, comprising the steps of:
 - a) measuring the activity of a compound of claim 89; and
 - b) measuring the same activity of lysophosphatidic acid or phosphatidic acid.
- 103. (Withdrawn) The method of claim 102, wherein the method comprises identifying agonists or antagonists of lysophosphatidic acid binding to or activating lysophosphatidic acid receptors of the edg class in a cell.
- 104. (Withdrawn) The method of claim 102, wherein the method comprises identifying agonists or antagonists of lysophosphatidic acid binding to or activating lysophosphatidic acid receptors of the non-edg class in a cell.